[{"abstract": "Shares of Shire tumble in London trading amid fears that a $54 billion deal \u2014 the biggest takeover this year \u2014 is in trouble.", "web_url": "https://dealbook.nytimes.com/2014/10/15/shire-urges-abbvie-to-pursue-merger-despite-new-inversion-rules/", "snippet": "Shares of Shire tumble in London trading amid fears that a $54 billion deal \u2014 the biggest takeover this year \u2014 is in trouble.", "lead_paragraph": "LONDON\u00a0\u2014 A day after the American drug maker\u00a0AbbVie disclosed that it was having second thoughts about its planned acquisition of Shire,\u00a0the Irish drug maker urged it to pursue the $54 billion deal.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1b-articleLarge-v2.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1b-articleLarge-v2.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1b-jumbo-v2.jpg", "height": 682, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1b-superJumbo-v2.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie1b/dbpix-abbvie1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Shire Urges AbbVie to Pursue Merger Despite New Inversion Rules", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Corporate Taxes", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "persons", "value": "Lew, Jacob J", "rank": 4, "major": "N"}, {"name": "persons", "value": "Obama, Barack", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Abbott Laboratories", "rank": 6, "major": "N"}, {"name": "organizations", "value": "AbbVie Inc", "rank": 7, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 8, "major": "N"}, {"name": "organizations", "value": "Covidien plc", "rank": 9, "major": "N"}, {"name": "organizations", "value": "Medtronic Inc", "rank": 10, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 11, "major": "N"}, {"name": "organizations", "value": "Salix Pharmaceuticals Ltd", "rank": 12, "major": "N"}, {"name": "organizations", "value": "Shire PLC", "rank": 13, "major": "N"}, {"name": "organizations", "value": "Steris Corporation", "rank": 14, "major": "N"}, {"name": "organizations", "value": "Treasury Department", "rank": 15, "major": "N"}, {"name": "glocations", "value": "Chicago (Ill)", "rank": 16, "major": "N"}, {"name": "glocations", "value": "Ireland", "rank": 17, "major": "N"}], "pub_date": "2014-10-15T09:05:01+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/d371a12d-3e0f-5a4b-8a5b-771563f40bc5", "word_count": 536, "uri": "nyt://article/d371a12d-3e0f-5a4b-8a5b-771563f40bc5"}, {"abstract": "The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future.", "web_url": "https://dealbook.nytimes.com/2014/10/15/abbvies-u-turn-shows-shire-deal-was-driven-by-taxes/", "snippet": "The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future.", "lead_paragraph": "AbbVie\u2019s U-turn shows its Shire deal was mostly about tax breaks, after all.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg", "height": 360, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 360}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-jumbo.jpg", "height": 614, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-superJumbo.jpg", "height": 1200, "width": 2000, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AbbVie\u2019s U-Turn Shows Shire Deal Was Driven by Taxes", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "AbbVie Inc", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Shire PLC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Treasury Department", "rank": 6, "major": "N"}], "pub_date": "2014-10-15T15:59:18+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Neil Unmack", "person": [{"firstname": "Neil", "middlename": null, "lastname": "Unmack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520", "word_count": 378, "uri": "nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520"}]